Brexpiprazole - A treatment for schizophrenia (RP Jan/Feb 2019)

Accredited CPD
Group 2

Provider: Retail Pharmacy 
Author: Margaret Robinson

CPD Credits: 2

Overview 

Designed to give an overview of Brexpiprazole, a second-generation antipsychotic.

Learning Objectives

After completing this activity, pharmacists should be able to:

1. describe the place in therapy of brexpiprazole compared to other second-generation antipsychotics and its mechanism of action

2. list dosing formulations, dosing regimens and any diminishment of its efficacy by failing body systems

3. recognise the adverse effects of brexpiprazole and the consequences of these adverse effects

4. describe the drug interactions that may affect the blood levels of brexpiprazole and also its effect on blood levels of the interacting drugs

The 2016 Competency Standards addressed by this activity include: 2.3, 3.1, 3.2, 3.3 and 3.6

Accreditation number: A1902RP2    Accreditation expires: 01/02/2021
This activity has been accredited for 1.0 hour of Group One CPD (or 1.0 CPD credit) suitable for inclusion in an individual pharmacist’s CPD plan, which may be converted to 1.0 hour of Group Two CPD (or 2.0 CPD credits) upon successful completion of the associated assessment activity.